Welcome to our dedicated page for Xbiotech SEC filings (Ticker: XBIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing XBiotech Inc.’s SEC disclosures can feel like decoding laboratory notebooks. Clinical-stage updates on its True Human monoclonal antibody pipeline, GMP facility costs, and cash-burn projections sprawl across hundreds of pages. Whether you’re after “XBiotech SEC filings explained simply,” need an “XBiotech quarterly earnings report 10-Q filing,” or want “XBiotech 8-K material events explained,” this page is built for you.
Stock Titan’s AI-powered summaries convert the dense narrative of an “XBiotech annual report 10-K simplified” into a concise brief and provide instant “XBiotech Form 4 insider transactions real-time” alerts. Interactive dashboards add “XBiotech earnings report filing analysis,” while point-and-click navigation drops you straight into an “XBiotech proxy statement executive compensation” section—all without leaving the filings page. Real-time EDGAR monitoring ensures you see each 10-Q, 8-K, S-3, or SC 13G the moment it’s accepted.
Use these tools to monitor “XBiotech insider trading Form 4 transactions,” compare phase-based R&D spending, or flag new shelf registrations. By “understanding XBiotech SEC documents with AI,” biotech-focused investors can focus on trial milestones instead of pagination. Integrated watchlists also surface “XBiotech executive stock transactions Form 4” next to clinical timeline charts, giving you context for strategic moves as they occur.
XBiotech Inc. reported narrower losses in the quarter ended June 30, 2025 with a three-month net loss of $1.8 million and a six-month net loss of $12.6 million, down from $13.0 million and $23.0 million a year earlier. Revenue remained nil and operating expenses fell as clinical trial activity decreased and certain executive compensation timing shifted; research and development totaled $5.3 million for the quarter and $17.0 million year-to-date. The company held $152.9 million in cash and cash equivalents at June 30, 2025, down from $172.7 million at December 31, 2024, and used $12.7 million of cash in operations during the six months ended June 30, 2025.
The company repaid and terminated a $10.0 million related-party convertible loan on January 31, 2025, extinguishing conversion rights. Total assets were $178.7 million and shareholders' equity was $173.1 million as of June 30, 2025. XBiotech states its cash is sufficient to achieve several major inflection points and to fund operations for at least 12 months from the report date.
XBiotech announced two significant appointments to its Board of Directors on June 24, 2025. The company has appointed Dr. Thomas Kündig and Craig Rademaker as new board members, with immediate effect until the 2025 Annual General Meeting.
Key appointments and roles:
- Dr. Kündig, Director of Dermatology at University Hospital Zurich, joins the Compensation Committee. He brings expertise in immunodermatology and pioneering work in intralymphatic immunotherapy (ILIT)
- Mr. Rademaker, a financial industry veteran with 25+ years experience, joins the Audit Committee. He currently leads a Private Equity firm managing assets over $5 billion
The updated committee structure now includes:
- Audit Committee: Jan-Paul Waldin, Dr. Peter Libby, and Craig Rademaker
- Compensation Committee: Jan-Paul Waldin, Dr. Peter Libby, and Dr. Thomas Kündig
FAQ
What is the current stock price of Xbiotech (XBIT)?
What is the market cap of Xbiotech (XBIT)?
